Clincosm LogoSign in Get a demo

iCLAS™ for Persistent Atrial Fibrillation

Sponsor
Adagio Medical (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04061603
Collaborator
(none)
200
Enrollment
20
Locations
1
Arm
36
Anticipated Duration (Months)
10
Patients Per Site
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)

Condition or Disease Intervention/Treatment Phase
  • Device: Adagio AF Cryoablation System (iCLAS™)
 N/A

Detailed Description

A staged pre-market, single-arm, clinical study designed to collect acute and long-term safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure. Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment at one, three, six, and twelve months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Symptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablationSymptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablation
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
iCLAS™ for Persistent Atrial Fibrillation
Actual Study Start Date :
Dec 9, 2019
Anticipated Primary Completion Date :
Dec 9, 2022
Anticipated Study Completion Date :
Dec 9, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: iCLAS Ablation

Ablation of the left and right atrium with the Adagio Medical iCLAS System

Device: Adagio AF Cryoablation System (iCLAS™)
Endovascular ablation of the left and right atrium

Outcome Measures

Primary Outcome Measures

  1. Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. [12-months]

    MAEs include any of the following: Death Myocardial infarction Cardiac perforation/pericardial tamponade Cerebral infarct or systemic embolism Major bleeding requiring transfusion of blood products Mitral or tricuspid valve damage Symptomatic pulmonary vein stenosis Severe (≥ 70%) pulmonary vein stenosis Permanent phrenic nerve injury Access site complications requiring pharmacological or surgical intervention Atrio-esophageal fistula Pericarditis Heart block requiring a permanent pacemaker Vagal nerve injury with GI dysmotility Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System

  2. Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT). [12-months]

    The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.

Secondary Outcome Measures

  1. Recording and analysis of all identified SAEs and SADEs through 12-months post-procedure. [12-months]

    Events will be sub-stratified based on time to event as follows: Early onset (procedure through 7-days post-ablation) Peri-procedure (> 7-days through 30-days post-ablation) Late onset (>30-days post ablation)

  2. Analysis of the proportion of subjects with acute procedural (ablation) success [20-minutes following last ablation]

    Documentation of pulmonary vein isolation and posterior wall isolation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

INCLUSION CRITERIA

IC1 Male or female between the ages of 18 and 80 years

IC2 Currently scheduled for an ablation of symptomatic, PsAF defined as continuous AF that is sustained > 7-days and ≤ 12 months and documented by the following: a. Physician's note indicating continuous AF > 7 days and ≤ 12 months, AND b. One of the following: i. 24-hour Holter within 180 days of enrollment showing continuous AF, OR ii. Two electrocardiograms from any forms of rhythm monitoring (e.g., 12-lead ECGs or single lead ECGs) completed ≥ 7 days apart within 180 days of enrollment.

IC3 Refractory to at least one class I or III AAD. (Refractory defined as not effective, not tolerated or not desired)

IC4 Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study

IC5 Willingness and ability to give an informed consent

EXCLUSION CRITERIA

EC 1 In the opinion of the Investigator, any known contraindication to an atrial ablation, TEE, or anticoagulation. Including, but not limited to, the identification of any atrial thrombus or evidence of sepsis

EC 2 Any duration of continuous AF lasting longer than 12-months

EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT

EC 4 Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause

EC 5 Structural heart disease as described below:

  1. Left ventricular ejection fraction (LVEF) < 40% based on most recent TTE

  2. Left atrial size > 55 mm (parasternal long axis view) documented within 6-months of screening

  3. NYHA Class III or IV heart failure documented within the previous 12-months

  4. An implanted pacemaker or ICD

  5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG),

  6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve

  7. Interatrial baffle, closure device, patch, or PFO occluder

  8. Presence of a left atrial appendage occlusion device

  9. Presence of any pulmonary vein stenting devices

  10. Coronary artery bypass graft (CABG) or PTCA procedure within 6 months prior to procedure

  11. Unstable angina or ongoing myocardial ischemia

  12. Myocardial infarction within the previous six (6) months prior to procedure

  13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE

  14. Atrial myxoma

  15. Significant congential anomaly

EC 6 BMI > 40

  • BMI >35 and no prior sponsor approval into the study

EC 7 Any previous history of cryoglobulinemia

EC 8 History of blood clotting or bleeding disease

EC 9 History of severe COPD requiring steroid use in the previous 12-months

EC 10 History of severe sleep apnea (AHI > 30) not currently treated with a CPAP machine or other mechanical device

EC 11 Any prior history of documented cerebral infarct including recent TIA (within one year) or systemic embolism (excluding a post-operative DVT)

EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis

EC 13 Pregnant or lactating (current or anticipated during study follow-up)

EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study

EC 15 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center, COVID-19 related concerns)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Grandview Medical Center Birmingham Alabama United States 35243
2 Banner Health Phoenix Arizona United States 85006
3 St. Bernards Medical Center Jonesboro Arkansas United States 72401
4 University of California San Diego San Diego California United States 92093
5 South Denver Cardiology Associates Denver Colorado United States 80120
6 Mayo Clinic Jacksonville Florida United States 32224
7 Emory St. Joseph's Hospital Atlanta Georgia United States 30342
8 Northwestern University Evanston Illinois United States 60208
9 Prairie Heart Research Institute Springfield Illinois United States 62701
10 Johns Hopkins University Baltimore Maryland United States 21205
11 Massachusetts General Hospital Boston Massachusetts United States 02114
12 The Valley Hospital Ridgewood New Jersey United States 07450
13 New Mexico Heart Institute Albuquerque New Mexico United States 87102
14 Ohio Health Research Institute Columbus Ohio United States 43214
15 Baylor St. Luke's Medical Center Houston Texas United States 77030
16 Onze Lieve Vrouwziekenhuis Aalst Belgium
17 ZNA Middelheim Antwerp Belgium
18 Southlake Regional Medical Centre Newmarket Ontario Canada L3Y 2P9
19 St. Antonius Ziekenhuis Nieuwegein Nieuwegein Netherlands
20 Erasmus University Medical Center Rotterdam Netherlands 3015 GD

Sponsors and Collaborators

  • Adagio Medical

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Adagio Medical
ClinicalTrials.gov Identifier:
NCT04061603
Other Study ID Numbers:
  • CS-200
First Posted:
Aug 20, 2019
Last Update Posted:
Feb 16, 2022
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:
Atrial Fibrillation

Study Results

No Results Posted as of Feb 16, 2022